Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
Open Access
- 1 June 2010
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (6) , 2030-2039
Abstract
Although metastasis is the leading cause of cancer-related death, it is not clear why some patients with localized cancer develop metastatic disease after complete resection of their primary tumor. Such relapses have been attributed to tumor cells that disseminate early and remain dormant for prolonged periods of time; however, little is known about the control of these disseminated tumor cells. Here, we have used a spontaneous mouse model of melanoma to investigate tumor cell dissemination and immune control of metastatic outgrowth. Tumor cells were found to disseminate throughout the body early in development of the primary tumor, even before it became clinically detectable. The disseminated tumor cells remained dormant for varying periods of time depending on the tissue, resulting in staggered metastatic outgrowth. Dormancy in the lung was associated with reduced proliferation of the disseminated tumor cells relative to the primary tumor. This was mediated, at least in part, by cytostatic CD8+ T cells, since depletion of these cells resulted in faster outgrowth of visceral metastases. Our findings predict that immune responses favoring dormancy of disseminated tumor cells, which we propose to be the seed of subsequent macroscopic metastases, are essential for prolonging the survival of early stage cancer patients and suggest that therapeutic strategies designed to reinforce such immune responses may produce marked benefits in these patients.Keywords
This publication has 72 references indexed in Scilit:
- Dormancy of metastatic melanomaPigment Cell & Melanoma Research, 2009
- Cancer micrometastasis and tumour dormancyAPMIS, 2008
- Systemic Spread Is an Early Step in Breast CancerCancer Cell, 2008
- Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Nature Reviews Cancer, 2007
- Lung metastasis genes couple breast tumor size and metastatic spreadProceedings of the National Academy of Sciences, 2007
- Dissecting the metastatic cascadeNature Reviews Cancer, 2004
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Metastasis genes: A progression puzzleNature, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000